Daniel Morillo

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications

Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study.

Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study.

Journal: Future oncology (London, England)
Published: August 30, 2026

Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study.

Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study.

Journal: Blood advances
Published: April 03, 2026

Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial.

Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial.

Journal: Blood
Published: March 25, 2026

DNMT3A variants are associated with the development of nodal TFH cell lymphoma, angioimmunoblastic-type after solid tumour occurrence.

DNMT3A variants are associated with the development of nodal TFH cell lymphoma, angioimmunoblastic-type after solid tumour occurrence.

Journal: British journal of haematology
Published: February 06, 2026

Cardiac Surveillance for Anthracycline Cardiotoxicity: Clinical Yield in Low-to-Intermediate Risk Patients: MATRIX Study.

Cardiac Surveillance for Anthracycline Cardiotoxicity: Clinical Yield in Low-to-Intermediate Risk Patients: MATRIX Study.

Journal: JACC. CardioOncology
Published: January 15, 2026

Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma.

Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma.

Journal: HemaSphere
Published: January 09, 2026

Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial.

Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial.

Journal: Haematologica
Published: October 21, 2025

CCL18: a potential immunosuppressive biomarker for prognosis in ABC diffuse large B-cell lymphoma.

CCL18: a potential immunosuppressive biomarker for prognosis in ABC diffuse large B-cell lymphoma.

Journal: Frontiers in immunology
Published: August 27, 2025

Derivation and External Validation of Objective Performance Status Among Patients With Metastatic Cancer.

Derivation and External Validation of Objective Performance Status Among Patients With Metastatic Cancer.

Journal: JCO oncology practice
Published: July 25, 2025

Effects of an Electronic Patient Reported Outcome Measures (e-PROMs) Program on Symptom Reporting, Use of Healthcare, and Overall Survival in Patients With Lymphoma: A Multicenter Prospective Study.

Effects of an Electronic Patient Reported Outcome Measures (e-PROMs) Program on Symptom Reporting, Use of Healthcare, and Overall Survival in Patients With Lymphoma: A Multicenter Prospective Study.

Journal: EJHaem
Published: June 30, 2025

Skin manifestations uncover underlying Follicular helper T-cell lymphoma, angioimmunoblastic-type in an immunosuppressed patient.

Skin manifestations uncover underlying Follicular helper T-cell lymphoma, angioimmunoblastic-type in an immunosuppressed patient.

Journal: Virchows Archiv : an international journal of pathology
Published: May 15, 2025

Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study.

Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study.

Journal: Blood
Published: April 01, 2025
Showing 1-12 of 43

Last Updated: 09/26/2026